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Abstract
Background: Endothelium-derived nitric oxide (NO) mediates the arterial dilation following a flow increase (i.e.
flow-mediated dilation, FMD), easily assessed in the brachial artery. NO is also involved in cerebral hemodynamics
and it is supposed to trigger vascular changes occurring during migraine. This study aimed at investigating
whether migraine patients present an altered response to NO also in the peripheral artery system.
Methods: We enrolled 21 migraineurs (10 with aura [MwA], 11 without aura [MwoA]), and 13 controls. FMD was
evaluated with ultrasound in all subjects by measuring the percentage increase of the brachial artery diameter
induced by hyperaemia reactive to sustained cuff inflation around the arm above systolic pressure. FMD values
were then normalized for shear stress.
Results: Normalized FMD values were higher in patients with MwA (28.5 10
-2%.s) than in controls (9.0 10
-2%.s) and
patients with MwoA (13.7 10
-2%.s) (p < 0.001). FMD was over the median value (19%) in 23.1% of controls, in 45.5%
of the MwoA patients, and in 90% of the MwA patients.
Conclusions: Migraineurs with aura present an excessive arterial response to hyperaemia, likely as an effect of an
increased sensitivity to endothelium-derived nitric oxide. This phenomenon observed peripherally might reflect
similar characteristics in the cerebral circulation.
Background
Migraine is a common disabling primary headache. Over
the past decades, several neuronal and vascular hypoth-
eses have been proposed to clarify its pathophysiology
[1]. Today, migraine is considered a neurovascular disor-
der and classified into migraine without aura (MwoA)
and migraine with aura (MwA); the latter is usually pre-
ceded, or sometimes accompanied, by focal neurological
symptoms [2].
The dilatation of the intracranial vessels, part of the
trigemino-vascular system, is a well-known vascular fea-
ture of migraine attacks [3]. It is thought to be part of a
basic pain-sensitizing proces se n g a g i n gt h en i t r i co x i d e
(NO) cascade. In fact, NO can trigger migraine pain [4]
and its liberation, due to glyceryl trinitrate administra-
tion, induces a more pronounced intracranial arterial
dilation in migraineurs than non-migraineurs [5].
Besides, some antimigraine drugs are supposed to act
through the inhibition of NO and of the cascade of
intracellular reactions triggered by NO [5].
Endothelium-derived NO is also considered the princi-
pal mediator of flow-mediated dilation (FMD), a phe-
nomenon characterized by artery dilatation in response
to a flow increase [6-8]. Although FMD precise mechan-
ism is not completely understood, the shear stress on
t h ev e s s e lw a l l sd e t e r m i n e db yaf l o wi n c r e a s ei ss u p -
posed to activate ion channels and the endothelial NO
synthase, with the subsequent generation of NO and
therefore a vasodilatation. FMD thus reflects the arterial
capability to self-regulate its tone in response to changes
in the local environment (i.e. physical and chemical sti-
muli in the lumen). FMD is easily assessed in the bra-
chial artery, but it is considered a marker of endothelial
function for the entire vascular tree [8-10]. Moreover,
NO dependent vasodilatation is also involved in the che-
moregulatory mechanisms subtending cerebral vasomo-
tor reactivity (VMR) to hypercapnia [10]. Patients with
MwA were reported to have a cerebral vasomotor
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and controls [11-13].
On the other hand, the possible role of NO and
endothelial dysfunction in patients affected by migraine
was explored so far in few studies with negative results
[14,15]. Nevertheless, the authors of these studies con-
cluded that a defined conclusion on this issue could not
be drawn.
T h ep r e s e n ts t u d ya i m e dt oi n v e s t i g a t ew h e t h e rt h e
vascular response to endothelium-derived NO differs in
controls, in patients with migraine without aura and
with migraine with aura.
Subjects
Twenty-one patients affected by migraine, 11 without
aura and 10 with aura, diagnosed according to IHS cri-
teria [2], and 13 healthy subjects were enrolled in the
study. At the time of examination, all included patients
were headache-free and during a migraine-drug withdra-
wal period of one week; all patients had discontinued
prophylactic medications for at least one month before
the study. All enrolled subjects underwent neurological
examination and endothelial function assessment, after
detailing past medical history and drug consumption.
Methods
We evaluated endothelial function by measuring the
change in forearm blood flow induced by flow mediated
dilation [16,17]; measurements were performed accord-
ing to guidelines [18].
A l le x a m i n a t i o n sw e r ep e r f o r m e db yas i n g l ee x p e r i -
enced vascular sonographer, who was unaware of the
subjects’ clinical background, using an ultrasound sys-
tem (Aplio 80 CV, Toshiba) with a broadband 8-14
MHz transducer. In our lab coefficient of variation for
FMD repeated measurements is 15%.
Because of circadian variations of peripheral vascular
tone, the FMD investigation was performed on all
patients between 8 and 9 AM in a quiet, temperature
controlled room (22°C to 24°C). All subjects were stu-
died after a 12-hour overnight fast. Smokers refrained
from smoking in the 12 hours preceding the study.
Vasoactive drugs were discontinued in the same time
period. Female subjects were investigated during the
first week of menstrual cycle [19]. Patients were head-
ache-free for at least 15 days at the moment of the
examination. No patient had a migraine attack in the
five days subsequent the examination.
With the patient in the supine position, the right bra-
chial artery was scanned over a longitudinal section, 3-5
cm above the elbow. Depth and gain settings were opti-
mized to identify the lumen-to-vessel wall interface. The
FMD was assessed by measuring the change in brachial
artery diameter after 50, 60 and 70 seconds of reactive
hyperemia, compared with baseline measurements, after
deflation of a cuff placed around the forearm that had
been inflated to 50 mm Hg above systolic blood pres-
sure for 5 minutes (figure 1). Arterial diameter was
determined as the internal dimension of the vessel wall
from the anterior-to-posterior interface between the
lumen and the intima. The mean diameter was calcu-
lated from three measurements of arterial diameter per-
formed at end-diastole incident with the R wave on a
continuously recorded ECG.
The response of the vessel diameter to reactive hyper-
emia (FMD) was expressed as a percent change relative
to the diameter before cuff inflation. However, FMD
depends on the shear stress on the blood vessels, which
is directly related to the velocity and the viscosity of the
blood but inversely related to the vessel diameter. Ves-
sels with different diameters may have the same flow
but substantially different levels of shear stress and thus
a different degree of stimuli for FMD. In other words,
FMD values derived from subjects with a comparable
endothelial function but with different vessel diameters
may results dissimilar. To avoid this bias, FMD raw
values need to be corrected for flow velocity and dia-
meter. A shear rate was then estimated as velocity
divided by diameter [20]. Peak shear rate, estimated as
peak flow velocity divided by baseline diameter, was cal-
culated to quantify the FMD stimulus in each subject.
FMD responses were normalized by dividing the maxi-
mal percentage change in diameter by the peak shear
rate [20].
The experimental protocol was approved by the Uni-
versity Ethical Committee, and all patients and controls
signed a written informed consent.
Analytic approach
To describe the characteristics of our populations we
used the mean with inherent standard deviation and
proportions for continuous and discrete variables,
respectively.
To compare the relationship between age and FMD
we used the Spearman’s correlation coefficient, while to
compare the mean FMD between gender and across the
three groups (controls, MwoA, and MwA) we used a
generalized linear model (GLM) with Tukey’s correction
for multiple comparisons and the median test. The
GLM approach was also used to evaluate differences of
t h eF M Di nt h e s eg r o u p st a k i n gi n t oa c c o u n ta g ea n d
gender, and to calculate adjusted means of the FMD
using the least-squares method.
Results
Overall, we evaluated 34 participants: 21 with migraine (10
with aura [MwA], 11 without aura [MwoA]), and 13 con-
trols. Mean age of the sample was 36.7 years (SD: 10),
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40.1 years, respectively), while controls were younger
(mean age: 30.5 years). The majority of participants were
women (28/34, 82%), with higher prevalence in the MwoA
group (10/11, 91%). Only four participants (3 in in the
group MwoA, one control) were active smokers, three (2
MwoA, 1 MwA) had hypertension, and two participants in
MwA group had dyslipidemia. None of the participants
had a diagnosis of diabetes mellitus.
As shown in table 1, basal systolic blood flow velocity
was higher in the control group compared to MwA
group (P < 0.05), but not compared to the MwoA
group. Post-ischemic systolic flow velocity and shear
rate showed a similar pattern, with lower values
observed in the MwA group compared to the control
group. Overall mean FMD was 20.9% (95% CI: 17.0% -
24.8%), with figures of 15.5% in controls, 18.2% in the
MwoA group, and 31.0% in the MwA group (P < 0.05
vs. both controls and MwoA). The median test con-
firmed the result (P < 0.001).
FMD was not correlated with age (Spearman’s correla-
tion coefficient: 0.118; P = 0.5), while women tended to
have higher mean FMD compared to men (respectively:
22.1%, 95% CI: 17.4% - 26.7%; 16.3%, 95% CI: 11.4% -
21.2%; P = 0.30). Results from a multivariable generalized
linear model adjusted for age and gender are similar to the
Table 1 Comparison of hemodynamic variables
Controls
Mean (95% CI)
Migraine
without aura
Mean (95% CI)
Migraine
with aura
Mean (95% CI)
Basal systolic blood flow velocity (cm.s
-1) 32.2
(25.9 - 38.4)
27.0
(20.2 - 33.8)
22.0
(16.2 - 27.8)*
Post-ischemic flow velocity (cm.s
-1) 47.0
(41.2 - 52.7)
41.3
(33.4 - 49.1)
34.6
(24.8 - 44.3)*
Baseline artery diameter (mm)
§ 2.74
(2.42 - 3.06)
3.15
(2.76 - 3.53)
3.13
(2.64 - 3.62)
Shear rate (s
-1) 177.0
(148.9 - 205.1)
134.6
(104.7 - 164.5)
119.2
(71.5 - 167.0)*
Flow mediated dilation (% of basal) 15.5
(13.3 - 17.6)
18.2
(14.1 - 22.3)
31.0
(21.7 - 40.3)*,
†
* P < 0.05 vs. controls
† P < 0.05 vs. MwoA
§Mean of 3 measurements
Figure 1 Ultrasound image of the brachial artery at (A) baseline and (B) 60 seconds after hyperaemic stimulus.
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means of FMD were 12.0% (95% CI: 6.0% - 18.0%) in the
control group, 16.3% (95% CI: 9.7% - 23.0%) in the MwoA
group, and 30.7% (95% CI: 23.9% - 37.5%) in the MwA
group (P < 0.01 vs. both controls and MwoA). Age and
gender were not associated with FMD in this model (P =
0.108 and P = 0.145, respectively).
The results did not change when we analyzed the
FMD normalized for the peak shear rate (figure 2): it
was 9.2 10
-2 %.s (95% CI: 7.5 - 10.9) in the control
group, 13.7 10
-2 %.s (95% CI: 11.1 - 16.4) in the MwoA
group and 28.5 10
-2 %.s in the MwA group (95% CI:
21.6 - 35.4) (P < 0.001). The corresponding least-squares
means adjusted for age and gender were 7.7 10
-2 %.s
(95% CI: 4.0 - 11.5), 15.0 10
-2 %.s (95% CI: 10.7 - 19.2),
and 30.5 10
-2 %.s (95% CI: 26.1 -34.8) (P < 0.001).
The proportion of subjects with FMD over the median
value (19%) was 23.1% in the control group, 45.5% in
the MwoA group (OR vs. control: 2.78; 95% CI: 0.48 -
16.03), and 90% in the MwA group (OR vs. control:
30.0; 95% CI: 2.62 - 342.73).
Discussion and Conclusions
The main finding of the present study is that patients
affected by migraine with aura show a higher FMD than
controls and migraineurs without aura. In addition, our
d a t as u g g e s tt h a tF M Dv a l u e sr a n g ew i t hc o n t i n u i t y
from controls to patients with MwoA to those with
MwA.
Flow mediated dilation is a physiological phenomenon
characterized by vessel dilatation in response to an
increase in blood flow, or more precisely to the shear
stress, a mechanical stimulus resulting from blood stream
along the endothelial cells [20]. An important mediator
of FMD is endothelium-derived NO [6-8]. Hyperemic sti-
muli induce the endothelium to release NO which acts
directly on arterial smooth muscle cells producing vaso-
dilatation. As mentioned before, NO is a potent endogen-
ous vasodilator, involved in pain transmission,
hyperalgesia, chronic pain, inflammation and central sen-
sitisation. It is also involved in migraine pathogenesis
causing an immediate headache in all migraine patients
and less often in healthy subjects [21-23]. In addition,
NO is released during cortical spreading depression
(CSD), playing a significant role in the hemodynamic
changes associated with this phenomenon [24-27].
Migraine patients seem to have an arterial super-sensi-
tivity to NO [5,28]. NO-containing nerve fibers have
been demonstrated around intracranial arteries suggest-
ing that NO probably plays a regulatory role in neuro-
peptide release (e.g. calcitonin gene-related peptide,
CGRP) [29,30], starting a neurogenic inflammatory pro-
cess. Consequently, an increased response to NO might
not only imply an excessive vasodilation by the direct
action of NO on the vessel wall, but also an excessive
release of CGRP from perivascular nerves induced by
NO.
Arterial super-sensitivity to NO may be explained also
by an autonomic dysfunction. Some authors [3,31]
reported a possible impairment of parasympathetic and,
in particular, sympathetic control of cerebral blood flow
in migraine patients. Muller and Marziniak [32] specu-
lated that this autonomic dysfunction could subtend the
disorder of cerebral autoregulation demonstrated in
migraine patients also by previous studies [33,34]. Lack-
ing a functional autonomic controls, cerebral vessels
would become over-sensible to NO as well as to other
chemical stimuli, such as CO2.T h i sh y p o t h e s i si ss u s -
tained by several studies describing an increased cere-
brovascular reactivity to hypercapnia in migraine
patients, particularly in those affected by MwA [10-13].
Thus, our findings are in line with those reported on
the cerebral circulation, supporting the theory that
patients affected by MwA present a substantial disorder
of autoregulation inducing a super-sensitivity to chemi-
cal stimuli (e.g. NO, CO2).
Previous studies have already investigated the
endothelial function and NO vascular response describ-
ing either a normal (14, 15, 35) or a reduced FMD
[36,37] in migraine patients respect to controls. How-
ever, two studies evaluated only patients affected by
MwoA [35,36], and two studies did not distinguish
between MwA and MwoA patients in their analytic
approach [14,37]. Only one study analysed the FMD
normalized for the peak shear rate [37], in order to cor-
rect FMD values for baseline diameter and peak flow
velocity. In our study MwA patients show a higher
FMD than controls and MwoA subjects both in terms
of percentage increase in diameter and of values nor-
malized for peak shear stress. Controls tended to have
higher shear rate compared to migraneurs, and this is
expected given the fact that migraneurs have slightly
greater artery diameter. Correction for this variable,
however, did not change our results.
Differently from all these previous studies that were
carried out by means of an ultrasound probe with a
frequency of 7.5 -10 MHz, we performed our examina-
tion with a higher frequency probe (14 MHz). In our
opinion, this issue is of remarkable importance since
higher frequency probes have greater imaging resolu-
tion when evaluating superficial vessels. In our case,
the brachial artery walls are located within few milli-
metres from skin surface. In this situation a probe
with a higher frequency allows for a more precise
detection of minimal calliper variation, while the
intima layer of the superficial wall of the artery can
not be accurately visualized with a lower frequency
probe, resulting in a less accurate measure.
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nitrates and nitrites in controls and patients affected by
MwA or MwoA during the asymptomatic period, find-
ing no differences in the three groups. Fasting nitrates
and nitrites were measured before FMD evaluation, thus
these findings do not exclude a higher release of NO in
migraine patients in response to a shear stress. More-
over, these data differ from those of D’Amico et al. [38]
who described a hyperactivity of L-arginine-NO
pathway.
However, these conflicting results do not invalidate
the interpretation of our findings. In fact, a high FMD
in patients with MwA could be the result of either an
increased release of NO induced by shear stress (nearly
impossible to measure locally) or of an arterial super-
sensitivity to NO. We favour the latter explanation, as it
Figure 2 FMD normalized for the peak shear rate in the three groups considered (controls, migraine without aura [MwoA], migraine
with aura [MwA]). Circles: individual values; middle horizontal tick: mean; bars: ± 1 SD.
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patients’ cerebral arteries present a hyper-reactivity to
chemical stimuli [11-13]. We can speculate that MwA
patients’ arteries are peculiarly characterized by a super-
sensitivity to chemical and physical stimuli throughout
the whole arterial system.
We are aware that the present study has some limita-
tions such as the small samples and the younger age in
controls (30.5 years) compared with patients (40.1 and
41.2 years). Another flaw of our study is that we cannot
raise any definite conclusion concerning a possible
increased sensitivity to endothelium-derived NO in
absence of a control experiment with an endothelium-
independent NO donor, namely GTN, which we were
not able to perform in our study setting.
Further studies are needed to verify if this super-sensi-
tivity plays a key role in determining the aura phenom-
enon and represents a risk condition for vascular events.
Moreover, a study investigating a larger population
would be necessary to confirm a continuum of endothe-
lial reactivity (i.e. FMD values) from controls to
migraine without aura to migraine with aura.
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